Monoclonal antibodyFDA-approvedInvestigational
Sacituzumab govitecan
How it works
Delivers chemotherapy directly to cancer cells, reducing harm to healthy cells.
Cancer types
Breast Cancer— All patients
Ovarian Cancer— All patients
Efficacy
Clinical trials have shown that sacituzumab govitecan can improve overall response rate and progression-free survival in patients with platinum-resistant disease.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Sacituzumab Govitecan for Mesothelioma Treatment | Lung Cancer | phase-2 | — | Source → |
| Study of New Treatments for Triple Negative Breast Cancer | Breast Cancer | phase-3 | — | Source → |
| Lung Cancer Treatment Trial for Patients with Residual Disease | Lung Cancer | phase-3 | — | Source → |
| Testing Atezolizumab and Sacituzumab Govitecan to Prevent Triple Negative Breast Cancer Recurrence | Breast Cancer | phase-2 | — | Source → |
| Testing Alpelisib and Sacituzumab Govitecan for Breast Cancer Treatment | Breast Cancer | phase-1 | — | Source → |
| Study Examines Side Effects of Cancer Treatment in Advanced Breast Cancer Patients | Breast Cancer | observational | — | Source → |
| Testing Treatments for Advanced Triple Negative Breast Cancer | Breast Cancer | phase-2 | — | Source → |
| Testing a New Combination Treatment for Certain Cancers | Lung Cancer | phase-1 | — | Source → |
| Sacituzumab Govitecan and Radiation Therapy Treat Choroidal Metastases in Triple Negative Breast Cancer | Breast Cancer | observational | — | Source → |
| Sacituzumab govitecan shows promise in rare breast cancer subtype | Breast Cancer | observational | The overall response rate was 36.4%, clinical benefit rate 45.5%, median progression-free survival 3.2 months and median overall survival 8.9 months. | Source → |
| Researchers Study How Cancer Drug Works in Breast Cancer Patients | Breast Cancer | phase-3 | — | Source → |
| Expert Consensus on Managing Side Effects of New Cancer Treatment | Breast Cancer | review | — | Source → |
| New Options for Treating Advanced Breast Cancer | Breast Cancer | review | — | Source → |
| Gene Mutation Affects Safety of Cancer Treatment | Breast Cancer | review | — | Source → |
| New Study Examines Effectiveness and Safety of Cancer Treatment in Triple-Negative Breast Cancer Patients | Breast Cancer | phase-1/2 | The model-predicted proportions of patients with complete response and objective response rate were 4.26% and 32.6%, respectively. | Source → |
| New Cancer Treatment Cost-Effectiveness Study in China | Breast Cancer | phase-3 | Sacituzumab govitecan provided an additional 0.25 QALYs and an incremental cost of $ 81,778.61 compared with chemotherapy. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.